[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
…, N Tanglakmankhong, J Tubprasert… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19
antiviral treatments, but their antiviral activities in patients have not been compared …
antiviral treatments, but their antiviral activities in patients have not been compared …
[HTML][HTML] Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
…, V Kruabkontho, T Ngernseng, J Tubprasert… - BMC Infectious …, 2024 - Springer
Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral …
Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)
…, S Boyd, V Kruabkontho, T Ngernseng, J Tubprasert… - ELife, 2023 - elifesciences.org
Background: There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment …
Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)
…, T Ngernseng, J Tubprasert… - The Journal of …, 2023 - academic.oup.com
Background Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
disease 2019 (COVID-19) has resulted in varying treatment guidelines. Methods In a …
[HTML][HTML] Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis …
…, V Kruabkontho, T Ngernseng, J Tubprasert… - The Lancet Infectious …, 2024 - thelancet.com
Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
…, V Kruabkontho, T Ngernseng, J Tubprasert… - medRxiv, 2022 - medrxiv.org
Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
COVID-19 has resulted in varying treatment guidelines. Early in the pandemic the monoclonal …
Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
…, S Boyd, V Kruabkontho, T Ngernseng, J Tubprasert… - medRxiv, 2022 - medrxiv.org
Background There is no generally accepted methodology for in vivo assessment of antiviral
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …
activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment …
Facilitating Safe Discharge through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): a prospective cohort study to develop and …
…, VK Singh, J Suri, S Suzuki, J Tubprasert… - Clinical Infectious …, 2022 - academic.oup.com
Background In locations where few people have received coronavirus disease 2019 (COVID-19)
vaccines, health systems remain vulnerable to surges in severe acute respiratory …
vaccines, health systems remain vulnerable to surges in severe acute respiratory …
Facilitating safe discharge through predicting disease progression in moderate COVID-19: a prospective cohort study to develop and validate a clinical prediction …
…, VK Singh, VK Singh, J Suri, S Suzuki, J Tubprasert… - medRxiv, 2021 - medrxiv.org
Background In locations where few people have received COVID-19 vaccines, health systems
remain vulnerable to surges in SARS-CoV-2 infections. Tools to identify patients suitable …
remain vulnerable to surges in SARS-CoV-2 infections. Tools to identify patients suitable …
Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
…, S Singh, V Kruabkontho, T Ngernseng, J Tubprasert… - medRxiv, 2024 - medrxiv.org
Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro, …
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro, …
